Danaher DHR Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Sales by Business | |||||
| Biotechnology | $7.29B+7.9% | $6.76B-5.8% | $7.17B-18.1% | $8.76B+2.2% | |
| Diagnostics | $9.94B+1.6% | $9.79B+2.2% | $9.58B— | —— | |
| Life Sciences | $7.33B+0.1% | $7.33B+2.6% | $7.14B— | —— | |
| Sales by Product | |||||
| Nonrecurring revenue | $4.44B-1.5% | $4.51B-13.4% | $5.21B-9.7% | $5.77B+1.8% | |
| Recurring revenue | $20.13B+3.9% | $19.37B+3.7% | $18.68B-10.5% | $20.88B+9.1% | |
| Sales by Geography | |||||
| High-growth markets | $7.02B+2.2% | $6.87B-4.5% | $7.19B-6.7% | $7.71B-0.8% | |
| North America | $10.36B+0.6% | $10.3B+3.4% | $9.96B-15.1% | $11.73B+19.7% | |
| Other developed markets | $1.25B-0.1% | $1.25B-1.3% | $1.27B-5.6% | $1.35B-0.9% | |
| Western Europe | $5.94B+8.8% | $5.46B-0.2% | $5.47B-6.7% | $5.86B-0.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Danaher break its business down?
- Danaher (DHR) reports sales by business across 3 parts — Biotechnology, Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Danaher's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Danaher's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
